Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis
Authors' conclusion
Denosumab has shown promising results in recent years in terms of reducing the size and activity of fibrous dysplasia lesions and improving bone markers. Further research is needed to better prevent the serious side effects sometimes associated with this treatment.
Study context
- Population
- Patients with fibrous dysplasia, alone or with McCune-Albright syndrome, treated with oral, subcutaneous or IV therapies; MEDLINE and Web of Science to February 3, 202656 studies
- Comparison
- Traditional vs new targeted therapies for fibrous dysplasia
- Outcome
- Lesion size or activity and circulating bone markers
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
- Studies showing a reduction in lesion size or activity
- almost three-quarters
- Studies showing a reduction in circulating bone markers
- 45/47
- Weighted mean reduction in alkaline phosphatase (n = 30)
- 31 ± 18%
Further pooled results
Fibrous dysplasia lesion activity on Na[18F]F PET-CT with DMAB
- Weighted mean reduction with DMAB
- 66 ± 15%
Safety
Serious side effects of new targeted therapies
- Some patients experienced serious side effects
Original publication
Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis. Osteoporos Int. Published 6 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →